Anti-RANKL Therapy Prevents Glucocorticoid-Induced Bone Loss and Promotes Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy

Bisphosphonates prevent bone loss in glucocorticoid (GC)-treated boys with Duchenne muscular dystrophy (DMD) and are recommended as standard of care. Targeting receptor activator of nuclear factor kappa-B ligand (RANKL) may have advantages in DMD by ameliorating dystrophic skeletal muscle function i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jayash, Soher Nagi, Hamoudi, Dounia, Stephen, Louise A., Argaw, Anteneh, Huesa, Carmen, Joseph, Shuko, Wong, Sze Choong, Frenette, Jérôme, Farquharson, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516841/
https://www.ncbi.nlm.nih.gov/pubmed/37470794
http://dx.doi.org/10.1007/s00223-023-01116-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516841/
https://www.ncbi.nlm.nih.gov/pubmed/37470794
http://dx.doi.org/10.1007/s00223-023-01116-w

Ejemplares similares